1. GPCR/G Protein
  2. Prostaglandin Receptor
  3. Ozagrel hydrochloride

Ozagrel hydrochloride  (Synonyms: OKY-046 hydrochloride)

Cat. No.: HY-B0428B Purity: 99.86%
Handling Instructions Technical Support

Ozagrel hydrochloride (OKY-046 hydrochloride) is a high selective and orally active thromboxane A2 (TXA2) synthase inhibitor with an IC50 of 11 nM. Ozagrel hydrochloride exerts anti-platelet aggregation, vasodilation and anti-inflammatory effects by inhibiting the production of TXA2 and increasing the production of prostacyclin (PGI2). Ozagrel hydrochloride can be used for the study of ischemic stroke, asthma and thromboembolic diseases.

For research use only. We do not sell to patients.

Ozagrel hydrochloride

Ozagrel hydrochloride Chemical Structure

CAS No. : 78712-43-3

Size Price Stock Quantity
Free Sample (0.1 - 0.2 mg)   Apply Now  
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Ozagrel hydrochloride:

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Ozagrel hydrochloride

View All Prostaglandin Receptor Isoform Specific Products:

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Ozagrel hydrochloride (OKY-046 hydrochloride) is a high selective and orally active thromboxane A2 (TXA2) synthase inhibitor with an IC50 of 11 nM. Ozagrel hydrochloride exerts anti-platelet aggregation, vasodilation and anti-inflammatory effects by inhibiting the production of TXA2 and increasing the production of prostacyclin (PGI2). Ozagrel hydrochloride can be used for the study of ischemic stroke, asthma and thromboembolic diseases[1][2][3][4][5].

IC50 & Target[1][5]

TXA2/TP

11 nM ()

TXB2

 

In Vitro

Ozagrel hydrochloride significantly inhibits platelet aggregation induced by Arachidonic acid (HY-109590) with an IC50 of 53.12 μM[1].
Ozagrel hydrochloride (100 μM) exhibits the inhibitory rate on plasma TXB2 of 99.6% but has no inhibitory effect on PGH2[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Ozagrel hydrochloride (10-20 mg/kg, p,o., once daily for 6-21 days) markedly improves extenuates endothelial dysfunction, oxidative stress and neuroinflammation in rat model of bilateral common carotid artery occlusion induced by L-Methionine (HY-N0326) and bilateral common carotid artery occlusion (BCCAo)[2][3].
Ozagrel (80 mg/kg, i,v., single dose) hydrochloride attenuates lung injury and decreases monocyte chemoattractant protein-1 and interleukin-8 mRNA expression in Oleic acid (OA) (HY-N1446)-induced lung injury in guinea pigs[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: VI-L-Methionine-induced vascular cognitive impairment and dementia (VCID) model established in Wistar rats of both sex and weighing 200 g[2]
Dosage: 10 and 20 mg/kg
Administration: Oral administration (p.o.), once daily for 21 days
Result: Improved the endothelial dysfunction caused by L-methionine-induced impairment.
Shortened the latency period of evasion, increased the duration of stay in target quadrants and reduced the length of swimming path.
Significantly reduced cerebral TBARS levels, increased cerebral GSH content, inhibited cerebral AChE activity, and decreased cerebral MPO activity and levels of TNF-α and IL-6.
Reduced leukocyte infiltration, neuronal degeneration and necrosis, increased pyramidal neuron density.
Animal Model: BCCAo induced vascular dementia (VaD) model established in Wistar rats of both sex and weighing 200 g[3]
Dosage: 10 and 20 mg/kg
Administration: Oral administration (p.o.), once daily for 6 days
Result: Improved the endothelial dysfunction caused by L-methionine-induced impairment.
Shortened the latency period of evasion, increased the duration of stay in target quadrants and reduced the length of swimming path.
Significantly reduced cerebral TBARS levels, increased cerebral GSH content, inhibited cerebral AChE activity, and decreased cerebral MPO activity and levels of TNF-α and IL-6.
Reduced neutrophil infiltration, alleviated neuronal degeneration and nuclear pyknosis, and improved vascular congestion state.
Animal Model: OA-induced lung Injury model established in male Hartley guinea pigs (420-500 g) [4]
Dosage: 80 mg/kg
Administration: Intravenous injection (i.v.), single dose, 3 h after OA injection
Result: Significantly reduced the levels of TXB2 in BALF and plasma.
Reduced the expression of MCP-1 and IL-8 mRNA and the infiltration of macrophages and neutrophils.
Significantly reduced the total protein concentration in BALF.
Clinical Trial
Molecular Weight

264.71

Formula

C13H13ClN2O2

CAS No.
Appearance

Solid

Color

White to off-white

SMILES

[H]Cl.O=C(O)/C=C/C1=CC=C(CN2C=CN=C2)C=C1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility
In Vitro: 

DMSO : 250 mg/mL (944.43 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H2O : 100 mg/mL (377.77 mM; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 3.7777 mL 18.8886 mL 37.7772 mL
5 mM 0.7555 mL 3.7777 mL 7.5554 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.08 mg/mL (7.86 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.08 mg/mL (7.86 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  PBS

    Solubility: 25 mg/mL (94.44 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
Purity & Documentation

Purity: 99.86%

References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
H2O / DMSO 1 mM 3.7777 mL 18.8886 mL 37.7772 mL 94.4430 mL
5 mM 0.7555 mL 3.7777 mL 7.5554 mL 18.8886 mL
10 mM 0.3778 mL 1.8889 mL 3.7777 mL 9.4443 mL
15 mM 0.2518 mL 1.2592 mL 2.5185 mL 6.2962 mL
20 mM 0.1889 mL 0.9444 mL 1.8889 mL 4.7221 mL
25 mM 0.1511 mL 0.7555 mL 1.5111 mL 3.7777 mL
30 mM 0.1259 mL 0.6296 mL 1.2592 mL 3.1481 mL
40 mM 0.0944 mL 0.4722 mL 0.9444 mL 2.3611 mL
50 mM 0.0756 mL 0.3778 mL 0.7555 mL 1.8889 mL
60 mM 0.0630 mL 0.3148 mL 0.6296 mL 1.5740 mL
80 mM 0.0472 mL 0.2361 mL 0.4722 mL 1.1805 mL
100 mM 0.0378 mL 0.1889 mL 0.3778 mL 0.9444 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Ozagrel hydrochloride
Cat. No.:
HY-B0428B
Quantity:
MCE Japan Authorized Agent: